- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Non.clinical study completion and manufacturing system development of CX301 for the development of orphan drug on malignant ischemic stroke | ||||||
| Others | Cerebral infarction | ROS.related inflammation | Preclinical | Cenyx Biotech Inc. | RS-2023-00284156 | ||
| 2 | Non.clinical development of ALS disease treatment using a small molecule compound that inhibits aggregation of SOD1 protein | ||||||
| Small Molecules | Amyotrophic Lateral Sclerosis | SOD1 | Preclinical | PRG S&Tech Inc. | RS-2023-00258714 | ||
| 3 | Pre-clinical development of AAV-CRISPR-based PMP22 normalization gene therapy for Charcot-Marie-Tooth 1A | ||||||
| Gene Therapy | Charcot-Marie-Tooth disease type 1A | PMP22 | Preclinical | ToolGen, Inc | HN22C0431 | ||
| 4 | Development of eIF4E ASO treating childhood intractable epilepsy as a first-in-class drug and establishment of R&D environment for RNA therapeutics | ||||||
| Gene Therapy | FCDII Refractory epilepsy | eIF4E | Preclinical | SoVarGen Co., Ltd. | HN21C0617 | ||